RBC Capital raised the firm’s price target on uniQure (QURE) to $20 from $14 and keeps an Outperform rating on the shares. uniQure announced that following its Type B meeting with the FDA, the Agency has agreed that data from its ongoing Phase I/II study may be sufficient for accelerated approval. Overall, RBC thinks the update materially de-risks the approach, shrinks timelines, and is likely to facilitate strategic discussions. The firm is a buyer into strength.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Wells upgrades uniQure on ‘high likelihood of success’ in Huntington’s
- uniQure upgraded to Overweight from Equal Weight at Wells Fargo
- Oracle reports mixed Q2, Gen Digital to acquire MoneyLion: Morning Buzz
- uniQure upgraded to Strong Buy at Raymond James after FDA alignment reached
- uniQure upgraded to Strong Buy from Outperform at Raymond James